The Latest Cardiac and Vascular News
PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business…
SAN FRANCISCO, CA, UNITED STATES, October 27, 2025 /EINPresswire.com/ — Solaris Endovascular, Inc., a U.S.-based, growth-stage medical device company pioneering next-generation endovascular stent-graft technology, today shared interim results from the DEScover Clinical Trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference. The data mark a major advance in the treatment […]
-$120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue -As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment -Attruby continues to differentiate clinically by proving its unique profile in new subpopulations and holistic analyses: -JACC publication demonstrated the effect of Attruby on cumulative cardiovascular outcomes within the first month of treatment -Positive topline interim analysis results from FORTIFY, the registrational Phase 3 study of BBP-418, a small molecule in development for LGMD2I/R9 -Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose of TX45 was well tolerated in this patient population and resulted in meaningful improvements in both left heart function and pulmonary hemodynamics.
SAN FRANCISCO–(BUSINESS WIRE)–PMcardio, a leader in AI-powered heart diagnostics, announced today that its Queen of Hearts™ algorithm demonstrated breakthrough accuracy in detecting acute heart attacks, known as STEMIs, in a major, multi-center U.S. validation study. The results, presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference and published in JACC: Cardiovascular Interventions, showed that the AI tool […]
BOSTON–(BUSINESS WIRE)–Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced the launch of its PlaqueIQTM image analysis software for the quantification and classification of plaque morphology in the carotid arteries. The first and only CT-based plaque analysis […]
Sparrow BioAcoustics today announced the closing of a $10 million financing round led by Killick Capital and Klister Credit, with participation from Pelorus VC, 98827 Newfoundland & Labrador Inc., and Brinex Capital. ST. JOHN’S, NL, Oct. 29, 2025 /PRNewswire/ – The new investment supports…
Landmark 12,000-patient study addresses critical gap in global healthcare: South Asian populations face heart disease at younger ages but are diagnosed with tools calibrated for Western genetics. Partnership aims to prevent heart attacks years before they occur. BENGALURU, India and…
MINNEAPOLIS, Oct. 29, 2025 /PRNewswire/ — VentureMed Group, Inc., a leading medical device company specializing in vessel preparation and access management technologies for the treatment of peripheral arterial disease (PAD) and arteriovenous fistulas and grafts (AVF, AVG), today…
Findings demonstrate safety, procedural success, and imaging-confirmed calcium modification using a next-generation laser intravascular lithotripsy (IVL) platform. MINNEAPOLIS, Oct. 29, 2025 /PRNewswire/ — FastWave Medical presented new first-in-human (FIH) and pre-clinical data for its…
